Lovastatin

Target genes for Lovastatin is obtained based on ToxCast assay component endpoints.
Chemical nameGene identifierToxCast assay component endpoint name
LovastatinNR1H3ATG_DR4_LXR_CIS_dn
LovastatinESR1CEETOX_H295R_TESTO_dn
LovastatinNACEETOX_H295R_TESTO_dn
LovastatinNACEETOX_H295R_ANDR_dn
LovastatinCCL26BSK_4H_Eotaxin3_down
LovastatinCOL3A1BSK_hDFCGF_CollagenIII_down
LovastatinCSF1BSK_hDFCGF_MCSF_down
LovastatinCSF1BSK_LPS_MCSF_down
LovastatinCYP19A1TOX21_Aromatase_Inhibition
LovastatinDIO1NHEERL_MED_hDIO1_dn
LovastatinEGFRBSK_hDFCGF_EGFR_down
LovastatinESR1TOX21_ERa_BLA_Antagonist_ratio
LovastatinESR1ATG_ERa_TRANS_up
LovastatinESR1ATG_ERE_CIS_up
LovastatinESR2TOX21_ERb_BLA_Antagonist_ratio
LovastatinESRRATOX21_ERR_Agonist
LovastatinF3BSK_3C_TissueFactor_down
LovastatinNR3C1TOX21_GR_BLA_Antagonist_ratio
LovastatinNR3C1CEETOX_H295R_11DCORT_dn
LovastatinNR3C1CEETOX_H295R_DOC_dn
LovastatinNR3C1CEETOX_H295R_CORTIC_dn
LovastatinHLA-DRABSK_3C_HLADR_down
LovastatinHLA-DRABSK_BE3C_HLADR_down
LovastatinHSF1TOX21_HSE_BLA_agonist_ratio
LovastatinICAM1BSK_KF3CT_ICAM1_down
LovastatinICAM1BSK_3C_ICAM1_down
LovastatinIL1ABSK_KF3CT_IL1a_down
LovastatinIL1ABSK_LPS_IL1a_down
LovastatinIL1ABSK_BE3C_IL1a_down
LovastatinCXCL8BSK_hDFCGF_IL8_down
LovastatinCXCL8BSK_3C_IL8_down
LovastatinCXCL8BSK_SAg_IL8_up
LovastatinCXCL10BSK_hDFCGF_IP10_down
LovastatinCXCL10BSK_BE3C_IP10_down
LovastatinCXCL10BSK_KF3CT_IP10_down
LovastatinARACEA_AR_antagonist_80hr
LovastatinARCEETOX_H295R_TESTO_dn
LovastatinARCEETOX_H295R_ANDR_dn
LovastatinARTOX21_AR_BLA_Antagonist_ratio
LovastatinJUNTOX21_AP1_BLA_Agonist_ratio
LovastatinKDRBSK_4H_VEGFRII_down
LovastatinESR1CEETOX_H295R_TESTO_dn
LovastatinFOSTOX21_AP1_BLA_Agonist_ratio
LovastatinNACEETOX_H295R_TESTO_dn
LovastatinSMAD1ATG_BRE_CIS_up
LovastatinARCEETOX_H295R_TESTO_dn
LovastatinARCEETOX_H295R_ANDR_dn
LovastatinCXCL9BSK_hDFCGF_MIG_down
LovastatinCXCL9BSK_BE3C_MIG_down
LovastatinNR3C2CEETOX_H295R_11DCORT_dn
LovastatinNR3C2CEETOX_H295R_DOC_dn
LovastatinNR3C2CEETOX_H295R_CORTIC_dn
LovastatinMMP1BSK_BE3C_MMP1_down
LovastatinMMP1BSK_hDFCGF_MMP1_down
LovastatinMMP9BSK_KF3CT_MMP9_down
LovastatinMTF1ATG_MRE_CIS_up
LovastatinNFE2L2ATG_NRF2_ARE_CIS_up
LovastatinNFE2L2TOX21_ARE_BLA_agonist_ratio
LovastatinSERPINE1BSK_hDFCGF_PAI1_down
LovastatinSERPINE1BSK_BE3C_PAI1_down
LovastatinPGRCEETOX_H295R_OHPROG_dn
LovastatinPGRTOX21_PR_BLA_Antagonist_ratio
LovastatinPIK3CANVS_ENZ_hPI3Ka
LovastatinPLATBSK_BE3C_tPA_down
LovastatinPLAUBSK_BE3C_uPA_down
LovastatinPLAUBSK_KF3CT_uPA_down
LovastatinPLAURBSK_BE3C_uPAR_down
LovastatinPLAURBSK_4H_uPAR_down
LovastatinPLAURBSK_3C_uPAR_down
LovastatinPOU2F1ATG_Oct_MLP_CIS_up
LovastatinRXRAOT_NURR1_NURR1RXRa_0480
LovastatinCCL2BSK_3C_MCP1_down
LovastatinCCL2BSK_SAg_MCP1_down
LovastatinCCL2BSK_CASM3C_MCP1_down
LovastatinCCL2BSK_KF3CT_MCP1_down
LovastatinCCL2BSK_4H_MCP1_down
LovastatinSELEBSK_LPS_Eselectin_up
LovastatinSELEBSK_SAg_Eselectin_up
LovastatinSELEBSK_3C_Eselectin_down
LovastatinSELPBSK_4H_Pselectin_down
LovastatinSREBF1ATG_SREBP_CIS_up
LovastatinTEKNVS_ENZ_hTie2
LovastatinTGFB1BSK_BE3C_TGFb1_down
LovastatinTGFB1BSK_KF3CT_TGFb1_down
LovastatinTHBDBSK_CASM3C_Thrombomodulin_up
LovastatinTIMP1BSK_hDFCGF_TIMP1_down
LovastatinTIMP2BSK_KF3CT_TIMP2_down
LovastatinTNFBSK_LPS_TNFa_down
LovastatinTP53TOX21_p53_BLA_p5_ratio
LovastatinTP53APR_HepG2_p53Act_24h_up
LovastatinTP53APR_HepG2_p53Act_72h_up
LovastatinNR1H2ATG_DR4_LXR_CIS_dn
LovastatinVCAM1BSK_3C_VCAM1_down
LovastatinVCAM1BSK_4H_VCAM1_down
LovastatinVCAM1BSK_LPS_VCAM1_down
LovastatinVCAM1BSK_hDFCGF_VCAM1_down
LovastatinVDRATG_VDRE_CIS_up
LovastatinNACEETOX_H295R_TESTO_dn
LovastatinNACEETOX_H295R_ANDR_dn
LovastatinNR1I2ATG_PXRE_CIS_up
LovastatinNR1I2ATG_PXR_TRANS_up
LovastatinCD38BSK_SAg_CD38_down
LovastatinCD40BSK_LPS_CD40_down
LovastatinCD40BSK_SAg_CD40_down
LovastatinCD69BSK_SAg_CD69_down
LovastatinNR1I3ATG_PBREM_CIS_up
LovastatinNR1H4NVS_NR_hFXR_Antagonist
LovastatinNR1H4ATG_IR1_CIS_dn
LovastatinNR1H4OT_FXR_FXRSRC1_0480
LovastatinNR1H4OT_FXR_FXRSRC1_1440

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.